Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)

CME information and select publications